Citadel Advisors LLC purchased a new position in Invizyne Technologies Inc. (NASDAQ:IZTC – Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 27,652 shares of the company’s stock, valued at approximately $456,000. Citadel Advisors LLC owned 0.44% of Invizyne Technologies as of its most recent filing with the Securities and Exchange Commission (SEC).
Separately, Geode Capital Management LLC bought a new position in Invizyne Technologies in the fourth quarter worth approximately $277,000.
Invizyne Technologies Price Performance
Shares of NASDAQ:IZTC opened at $13.40 on Tuesday. Invizyne Technologies Inc. has a 52-week low of $8.50 and a 52-week high of $23.00. The business’s 50 day moving average is $12.08 and its 200 day moving average is $14.14.
Invizyne Technologies Profile
Invizyne Technologies Inc is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc is based in Monrovia, CA.
Read More
- Five stocks we like better than Invizyne Technologies
- Dividend Capture Strategy: What You Need to Know
- Ulta’s Beautiful Q1 Earnings Report Points to More Gains Ahead
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Top 3 ETFs Defense Hawks Are Buying
- The 3 Best Fintech Stocks to Buy Now
- Zscaler Will Hit $360 Soon: Here’s the How and Why
Receive News & Ratings for Invizyne Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invizyne Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
